Ring Therapeutics is a pioneering startup that operates in the biotechnology sector, specifically in the development of programmable genetic medicines. The company's innovative approach involves the use of a commensal virus platform, known as Anellogy™, to engineer viral-based therapies. These therapies are designed to safely and effectively deliver treatments to targeted cells and tissues in the human body.

Ring Therapeutics' business model revolves around the development and commercialization of these viral-based therapies. The company's primary clients are patients with significant medical needs who could benefit from these innovative treatments.

The company's unique approach involves harnessing the power of anelloviruses, a type of virus that has evolved over millions of years to be extraordinarily diverse and capable of evading the human immune system. These viruses are not only ubiquitous within the human population, but they also exist in all tissues in the body. By leveraging these unique properties, Ring Therapeutics is developing therapies that can deliver diverse therapeutic modalities to a wide array of tissues.

The company's revenue model is likely based on the sales of these therapies once they have been developed, tested, and approved for use. Given the innovative nature of these therapies, they could potentially command high prices in the market, leading to substantial revenue for the company.

In summary, Ring Therapeutics is a biotech startup that is pushing the boundaries of medicine by developing programmable genetic therapies based on anelloviruses.

Keywords: Biotechnology, Programmable Genetic Medicines, Anellogy™, Viral-Based Therapies, Anelloviruses, Tissue Tropism, Payload Versatility, Potency, Redosability, Therapeutic Modalities.